Baxter reports Q2 sales jump, narrows earnings guidance
Q2
Pharma delivers another beat & raise quarter for Johnson & Johnson
Biomet moves to Q4, 2014 black
Biomet said yesterday that it put black ink back into its books for the fiscal 4th quarter and 2014, with adjusted profits rising by double digits.
Layoffs continue for Analogic; shares sink following Q2 earnings report, flat outlook
CareFusion affirms full-year outlook amid 10% profit slide in Q2
Analysts are taking a cautious approach to CareFusion (NYSE:CFN) amid increasing costs and a 10% drip in profits for the company’s 2nd quarter.
Biomet’s revised earnings show much wider losses than previously reported
Biomet amended its Q4 and annual earnings report to reflect a swing to red in Q4 and much deeper losses for the full year compared to earlier reports.
The Warsaw, Ind.-based orthopedics company posted losses of $221.2 million on $784 million in sales during the 3-month period ended May 31, 2013. An initial earnings report released in July had reported a $20.5 million profit for the quarter.
Tengion’s Q2 losses widen
Medtronic dips on missed Q1 revenues
Investors pushed shares of Medtronic (NYSE:MDT) down this morning after the world’s largest pure-play medical device company reported mixed results for its fiscal 1st quarter.
Fridley, Minn.-based Medtronic posted profits of $953 million, or 93¢ per share, on sales of $4.08 billion for the 3 months ended July 26. That’s a 10.3% top-line gain on 1.9% sales growth.
Operating profits rise for KCI despite Q2 sales slide
Operating profits rose 13.1% during the 2nd quarter for Kinetic Concepts Inc., despite a nearly 4% sales decline for the wound management company.
San Antonio, Texas-based KCI reported operating profits of $110.8 million on sales of $317.8 million for the 3 months ended June 30, according to a regulatory filing.
Syneron takes a hit on Q2 stumble
Syneron Medical Ltd. (NSDQ:ELOS) stumbled during the 2nd quarter, posting earnings that were even with Wall Street’s forecast but just missing sales expectations, sending share prices down this week.
Bovie Medical swings to Q2 red on legal loss to ex-counsel Keen
Bovie Medical (NYSE:BVX) put some red ink in its ledger for the 2nd quarter, largely due to a more than $1 million charge stemming from a legal loss to its former top lawyer.
